🇺🇸 FDA

Company profile · Sponsor

Aquestive

Aquestive Therapeutics

AQST · NYSE pharma WARREN, NJ, USA
Pipeline
9
Drugs
1
Patents
8

Quick answer

Aquestive (AQST) is a pharma company. headquartered in WARREN, NJ, USA. listed on NYSE. NovaPharmaNews links 9 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker AQST
Exchange NYSE
Company type pharma
Headquarters WARREN, NJ, USA
SEC CIK 0001398733

Pipeline (9)

Search pipeline →

  1. Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category

    Aquestive

    Epilepsy

    phase 3 small molecule completed

    1 trial

  2. DESF

    Aquestive

    Allergic Reaction

    phase 2 small molecule completed

    1 trial

  3. Diazepam Buccal Film

    Aquestive

    Epilepsy

    phase 2 small molecule completed

    2 trials

  4. Diazepam Buccal Film 12.5 mg

    Aquestive

    Epilepsy

    phase 2 small molecule completed

    1 trial

  5. Ondansetron (ODFS)

    Aquestive

    Nausea and Vomiting, Postoperative

    phase 2 small molecule completed

    1 trial

  6. Riluzole Oral Soluble Film

    Aquestive

    ALS

    phase 2 small molecule terminated

    1 trial

  7. Riluzole Oral Soluble film (ROSF) 50 mg

    Aquestive

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule terminated

    1 trial

  8. Ondansetron (ODFS)

    Aquestive

    Healthy

    phase 1 small molecule completed

    1 trial

  9. Ondansetron 8 mg ODFS without water

    Aquestive

    Healthy Participants

    phase 1 small molecule completed

    1 trial

Drugs (1)

Search drugs →

  1. riluzole

    RILUTEK

    ORAL approved

    N07XX02

Patents (8)

Search patents →

  1. US 12427121

    Enhanced delivery epinephrine compositions

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12403090

    Oral film compositions and dosage forms having precise active dissolution profiles

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12290597

    Oral film compositions and dosage forms having precise active dissolution profiles

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12023309

    Enhanced delivery epinephrine compositions

    Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11541002

    Oral film compositions and dosage forms having precise active dissolution profiles

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11273131

    Pharmaceutical compositions with enhanced permeation

    Expires Mon Mar 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11191737

    Enhanced delivery epinephrine compositions

    Expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11129799

    Dual lane coating

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Aquestive?

Aquestive (AQST) is a pharma company. headquartered in WARREN, NJ, USA. listed on NYSE. NovaPharmaNews links 9 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Aquestive sponsor?

We track 9 ClinicalTrials.gov-linked programs for Aquestive, including Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category and 8 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Aquestive company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.